Oncology

The authors emphasize that additional research addressing disparities and including race, age, and ethnicity should be conducted.

Despite the increased survival rates in all 4 evaluated racial groups, both adult and pediatric non-Hispanic African American patients continued to have worse outcomes.

Scott Soefje discusses new treatment options for prostate cancer and highlights the important role pharmacists can play in coordinating care.

The vice president of pharmacy operations at American Oncology Network says that pharmacists can contribute by educating patients and offering resources for support and treatment adherence.

The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.

With 50 biosimilar products approved by the FDA, questions arise regarding biosimilar lifecycles and sustainability of the industry.

The investigators note that additional research is needed to confirm positive overall survival trends in this patient population.

Tisotumab vedotin-tftv is the first antibody-drug conjugate to demonstrate positive overall survival data in patients with previously treated recurrent or metastatic cancer.

According to the speaker, the complexity of immune-related adverse events resulting from immune checkpoint inhibitors requires a lot of collaborative discussion between patients and providers.

Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.

Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.

This year’s event from June 20 to 21, 2024, in Austin, Texas, will offer 4.25 BCOP CE hours.

Advances, challenges, and promising innovations emerge.

A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.

Successful integration demands overcoming various hurdles.

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.

PAPs in this model can significantly reduce OOP costs regardless of the pharmacy setting.

The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.

The significant surge in oncology drug shortages in 2023 particularly affected essential chemotherapeutic drugs.

Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.

Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.

With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.

Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.

The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.

Through recognizing the importance of research in the scope of pharmacy practice by national pharmacy organizations, research can become a prominent role and responsibility of pharmacy.

Enfortumab vedotin in combination with pembrolizumab showed a manageable safety profile and promising progression free survival and overall survival for locally advanced or metastatic urothelial cancer.

The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.